Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
CTA-101 by Nanjing Bioheng Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
CTA-101 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...